New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Passage Bio, Inc. (PASG) vs Radiopharm Theranostics Limited - Sponsored ADR (RADX)

Passage Bio, Inc. and Radiopharm Theranostics Limited - Sponsored ADR are both Biotechnology companies. Passage Bio, Inc. and Radiopharm Theranostics Limited - Sponsored ADR are of similar size ($11.6M and $10.6M). Across the 3 metrics below, Radiopharm Theranostics Limited - Sponsored ADR leads on 2 and Passage Bio, Inc. on 1.

Valuation

Metric PASG RADX Biotechnology median
P/E n/m — 8.49
P/S — — 8.56
P/B 253.58 — 2.04
Price to free cash flow n/m — 23.84
EV/EBITDA 0.21 — 0.69
EV/Sales — — 8.00
Earnings yield (262.60%) — (35.81%)
Free cash flow yield (257.29%) — (25.41%)

Profitability

Metric PASG RADX Biotechnology median
Gross margin — — 70.18%
Operating margin — — 0.00%
Net margin — — 0.00%
Free cash flow margin — — 0.00%
Return on equity (212.27%) — (51.58%)
Return on assets (69.68%) — (45.91%)
Return on invested capital 0.00% — 0.00%

Growth

Metric PASG RADX Biotechnology median
Revenue growth (TTM) — — 7.20%
EPS growth (last fiscal year) 32.94% (1.97%) 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric PASG RADX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.00 1.16 4.79
Net debt to EBITDA 0.96 0.08 1.01

Dividend

Metric PASG RADX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PASG RADX Biotechnology median
Market cap 11.62m 10.57m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack